Second malignancies are uncommon events in the survivors of allogeneic transplant procedures, although they are increased compared to normal control populations. Among these malignancies, sarcomas are exceedingly rare. In addition, relapse of primary myelodysplasia rarely occurs after 5 years from the time of allogeneic transplantation. This report describes an unusual presentation of liposarcoma with concomitant relapse of underlying myelodysplasia developing in a patient 9 years after the first of two allogeneic transplantations.
transplantation
Secondary solid malignancies are an uncommon complication of stem cell transplantation. In comparison to normal control populations, the risk has been reported to be as much as 8.3 times higher at 10 years. 1 This increased risk has been associated with the use of pretransplant irradiation, 1,2 age of donor, the presence of chronic graftversus-host disease (GVHD) (in buccal cancers only), and the use of immunosuppressive agents such as cyclosporine 3 and antithymocyte globulin. 4 In the Fred Hutchison Cancer Research Center (FHCRC) and the International Bone Marrow Transplant Registry (IBMTR) cohort of over 19 000 patients, the most common of these solid tumors were squamous cell carcinomas of the skin and buccal cavity. Melanoma (11 cases), thyroid cancers (eight), CNS tumors (11) , and sarcomas (nine) were less frequently seen, with only four cases reported of soft tissue sarcomas. 1 Relapses from underlying hematologic malignancies are also extremely infrequent events when examined more than 5 years after allogeneic transplantation. For those surviving 2 years after allogeneic transplantation for acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), or aplastic anemia, only 4.5% of the 6691 patients reported died of late relapse, of which many of those relapses had occurred prior to the 5 year transplant anniversary. 2 Another series studying only patients transplanted for myelodysplasia reported no relapses after three years. 5 In this case report, we provide details of an unusual case of a high-grade liposarcoma that presented 7 and 9 years after two allogeneic transplants, and concurrently with the relapse of his primary hematologic disease.
Case report
The patient was a 59-year-old male who was 9 years statuspost allogeneic bone marrow transplant from an HLAidentical, ABO-incompatible brother for myelodysplastic syndrome (RA), original cytogenetics normal. His conditioning regimen was cyclophosphamide (120 mg/kg) and total body irradiation (TBI; 1200 cGy) with GVHD prophylaxis of cyclosporine (CSA) and methotrexate. This course was complicated by mild acute GVHD of the skin at day þ 75, which responded to immune suppression therapy. After 18 months, the patient developed progressive thrombocytopenia, which was initially diagnosed as idiopathic thrombocytopenia purpura. He responded to a course of corticosteroids, but worsening thrombocytopenia led to clinical re-evaluation. Chimerism studies detected 30% host cells, consistent with relapse of his MDS. Cytogenetics remained normal. Immune suppression was discontinued, but follow-up chimerism detected 100% host marrow cellularity. The patient underwent a peripheral blood stem cell transplant from the same sibling donor (19 months after his first transplant) in December 1996 with busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg) conditioning. GVHD prophylaxis included CSA and prednisone. This transplant was complicated by both grade II aGVHD, and subsequent severe cGVHD of the skin and gut. These episodes were treated with prolonged FK506 and prednisone, with good response. His course was further complicated by Cytomegalovirus (CMV) esophagitis, successfully treated with ganciclovir. No evidence of the underlying myelodysplasia was found and, after 5 years, the patient was thought to be cured. At 9 years after his first transplant, the patient presented in March 2003 with a 1-month history of marked fatigue, anorexia, 30-lb weight loss, night sweats, and migratory right-sided abdominal pain, worse when lying supine. His hematocrit and platelet count, previously normal, had fallen to 30.1% and 130 000/mm 3 . An abdominal CT scan revealed a 5 cm mass surrounding and infiltrating the lower pole of the right kidney. A CT-guided biopsy was interpreted as a sarcoma with myxoid features. Open resection of the tumor was performed with resection of the tumor and right kidney, omentectomy, and partial excision of the right psoas muscle. The pathologic diagnosis was high-grade dedifferentiated liposarcoma measuring 12.5 cm in greatest dimension (Figure 1 ). Surgical margins were positive for microscopic residual disease. The histologic features included areas of pleomorphic spindle cells, some myxoid areas, and areas of well-differentiated liposarcoma. The histologic sections showed relatively abrupt transition from a well-differentiated liposarcoma to a pleomorphic sarcoma, which is the hallmark of a dedifferentiated liposarcoma (Figure 2) . Immunoperoxidase stains supported the diagnosis; the tumor cells stained strongly only with vimentin and were negative for smooth muscle actin, desmin, S-100, DC34, CD117, and keratin cocktail. The tumor karyotype revealed complex cytogenetic abnormalities. Further analysis included immunohistochemical staining, which revealed surface expression of the TGF receptor and expression of TGF-b2. Staining for TGF-b3 and TGF b1 was negative (Figure 3) .
During hospitalization for this newly discovered sarcoma, the patient developed worsening thrombocytopenia, with platelet counts falling to below 50 000/mm 3 . Bone marrow revealed a cellularity of 20-30%, adequate megakaryocytes, no increased blasts, and no evidence of dysplasia. Karyotyping revealed that 14 of 20 metaphase cells analyzed were derived from an abnormal clone differing from the pretransplant myelodysplastic clone [t(l2;9) (p13;q22), del 13 q 12-14 m, add 19 p13]. VNTR revealed the marrow to be 80% host material. He developed worsening cytopenias and became dependent upon RBC and platelet transfusions. Within 3 months of surgery, he presented with progressive back pain, and was found to have a massive recurrence of his sarcoma. CT revealed a large lobulated mass in the vacated right renal bed, extending to the iliac crest and invading the posterior musculature, as well as several liver metastases. He died within 2 months of this recurrence of progressive sarcoma. 
Discussion
Solid tumors, as a subset of tumors developing after stem cell transplantation, are an extremely rare complication. [1] [2] [3] [4] The largest sample from the FHCRC and IBMTR databases report an eight-fold increase in connective tissue solid tumors after 10 years. 1 In general, soft tissue sarcomas of the abdominal cavity are an uncommon subset of sarcomas, representing o15% of all sarcomas. Unfortunately, these often have a worse prognosis than other sarcomas because of their advanced stage at the time of diagnosis and difficulty of resection. Patients who cannot undergo complete resection have 5-year survivals of less than 20%. 6 High-grade lesions also confer a worse prognosis than lower-grade lesions. 7 Late relapse of primary myelodysplasia also is exceedingly rare when one reviews the literature. The presentation of high-grade liposarcoma at the same time as the relapse of the patient's myelodysplasia is intriguing, since development of secondary malignancies and relapse of primary disease are not usually concurrent. It is unclear from this one case whether or not these are coincidental circumstances, or whether there is a causal or synergistic relationship between his sarcoma and his MDS relapse, which we suspect. This patient had exposure to radiation, which could have contributed to the development of the liposarcoma. It is also conceivable that cytokines elaborated by his sarcoma contributed to the recurrence of his myelodysplasia due to the effects on the immune system. Similar hypotheses have been considered to explain the presentation of relapses of acute leukemia at the time of pregnancy, as well as spontaneous remissions occurring with termination of pregnancy. 8, 9 Consistent with this hypothesis is the fact that the liposarcoma was found to express the TGF receptor and secrete TGF-a2. Although TGF-b acts as a tumor suppressor in normal cells, TGF-b production by malignancies has been reported to suppress the proliferation and activation of leukocytes, helping tumors to escape immunosurveillance. 10 For example, in osteosarcomas, increased TGF-b expression has also been associated with disease progression and metastasis. 10, 11 Perhaps (and similar to our case), other soft tissue sarcomas use the same mechanism, which at least in some tumors appears to be through a TGF-b autocrine loop, an idea supported in our case by the presence of both TGF-b and the TGF receptor on the sarcoma cell. 12, 13 With these considerations, it can be speculated that the biologic benefit from donor immune engraftment (graft vs malignancy effect) may not be eradication of underlying malignancy, but rather successful suppression, similar to the recognized suppression of autoreactive immune effector cells in all individuals. Thus, when the donor:host immune homeostasis is destabilized, as in this case with the high tumor burden of the liposarcoma and its potential immune suppressive cytokines, relapse is experienced with an evolved host myelodysplastic clone selected for its aggressive phenotype.
In summary, we report a case of an undifferentiated retroperitoneal liposarcoma diagnosed concurrently with relapse of myelodysplasia in a patient exposed to TBI (the likely etiologic agent of the liposarcoma), and status post two allogeneic stem cell transplants. The concurrent and late presentation of these two disorders raises interesting questions about the nature and impact of secondary solid malignancies on patients primarily transplanted for hematologic disorders. Given the infrequency of both independent events, it suggests that these are linked. If so, we hypothesize that the liposarcoma, possibly with its tumorassociated immune suppressive cytokines, could have disrupted the donor immune system leading to relapse of the primary myelodsyplasia. Thus, this single case might suggest that the immunologic graft vs malignancy effect may not always lead to eradication of the underlying primary malignancy, but, rather, contribute to its long-term suppression.
